The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
10X Genomics, Inc. | CLASS A COMMON | 88025U109 | 181,000 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 | ||
Acceleron Pharma Inc. | COM | 00434H108 | 2,590 | 19,100 | SH | SOLE | 19,100 | 0 | 0 | ||
Epizyme, Inc. | COM | 29428V104 | 2,559 | 293,759 | SH | SOLE | 293,759 | 0 | 0 | ||
Novavax, Inc. | COM | 670002401 | 12,113 | 66,810 | SH | SOLE | 66,810 | 0 | 0 |